<乌鸦传媒>Low Risk and Bicuspid Anatomy: A Passable Combination for TAVR Thus Far Clinical outcomes not worse compared with tricuspid TAVR Sep 21, 2021
<乌鸦传媒>With HVAD Out, Innovation Key to Mechanical Circulatory Support A debate on where LVAD innovation stands Sep 14, 2021
<乌鸦传媒>Transplant Docs Are Sticking With Invasive Biopsies After Heart Transplants Agreement that non-invasive alternatives to EMB are not ready for routine rejection surveillance Sep 13, 2021
<乌鸦传媒>SGLT2 Inhibitor Eases Symptoms for HFpEF Patients Trial suggests hard outcomes not the only ones helped by this class of medication Sep 13, 2021
<乌鸦传媒>Second-Gen Drug for HCM Emerges, Nipping at Mavacamten's Heels Novel cardiac myosin inhibitor is headed for a phase III trial Sep 12, 2021
<乌鸦传媒>Heart Failure's 'Golden Moment' Not Translating into Better Health Problems of implementation and health equity persist Sep 12, 2021
<乌鸦传媒>Feared ARNI Effect on Cognition Hasn't Come to Fruition Neurocognitive protection by sacubitril/valsartan suggested instead by observational study Sep 12, 2021
<乌鸦传媒>Good Results When Giving Flu Shots to MI Survivors Still in the Hospital Vaccination prior to discharge linked to heart benefit Aug 30, 2021
<乌鸦传媒>Polypills Ready for Prime Time in Large Swaths of People, Researchers Say Question now is how to implement fixed-dose combo therapy in clinical practice Aug 29, 2021
<乌鸦传媒>His Bundle Pacing Stars in European Guidelines Revised edition could signal coming U.S. recommendations too Aug 29, 2021
<乌鸦传媒>Ablation, CRT Boost Survival in Permanent Afib With Narrow QRS APAF-CRT trial reinforces the case for expanded CRT indication Aug 28, 2021
<乌鸦传媒>Revamped Valve Disease Guideline: Europe Sees Nearly Eye to Eye With U.S. There is a different approach to deciding the suitability of TAVR, however Aug 28, 2021
<乌鸦传媒>A Familiar Drug Can Keep Early-Stage HCM at Bay Treatment with valsartan most beneficial when started early? Aug 27, 2021
<乌鸦传媒>Empagliflozin Improves Outcomes in HFpEF Patients "A major win" for heart failure with preserved ejection fraction, says editorialist Aug 27, 2021
<乌鸦传媒>New Heart Failure Guidelines Released, but Are They Already Out of Date? Results of EMPEROR-Preserved contradict guidance Aug 27, 2021
<乌鸦传媒>Milder Heart Failure Might Benefit From Implantable Monitors Randomized trial signals benefit, albeit hampered by the pandemic Aug 27, 2021
<乌鸦传媒>Deadly Arrhythmias Less of a Risk for HF Patients on Dapagliflozin DAPA-HF analysis further explores mechanism of SGLT2 inhibitor's heart benefits Aug 27, 2021
<乌鸦传媒>Heart Failure Again Takes Center Stage at ESC EMPEROR-Preserved, new guidelines, and more to come Aug 26, 2021
<乌鸦传媒>Inotrope Showdown Leaves No Winner in Cardiogenic Shock Long-awaited head-to-head comparison of milrinone and dobutamine Aug 04, 2021
<乌鸦传媒>TAVR Debris Deflector Doesn't Fly With FDA Advisory Panel TriGuard 3 met with skepticism in its bid for approval Aug 04, 2021
<乌鸦传媒>Start Rhythm Control Early for Afib With Heart Failure EAST-AFNET 4 trial finds similar benefits across ejection fraction ranges Jul 31, 2021
<乌鸦传媒>SGLT2 Inhibitor Adds Years of Life to Patients With Heart Failure DAPA-HF group makes projections as long-term data are lacking Jul 28, 2021
<乌鸦传媒>Changes in Epicardial Fat May Drive SGLT2 Inhibitor Benefits More insight into mechanisms behind empagliflozin's cardioprotection Jul 26, 2021
<乌鸦传媒>Surprising Tradeoffs of Valve-in-Valve TAVR vs Redo Surgery Observational study suggests excess readmissions with less invasive procedure Jul 23, 2021
<乌鸦传媒>Does COAPT Change the Need to Try Foundational HF Drugs in Functional MR? Current GDMT titration approach under fire during TVT debate Jul 21, 2021
<乌鸦传媒>After Some Early Successes for Bicuspid TAVR, a Randomized Trial May Be Unlikely Are observational data on highly selected patients good enough? Jul 21, 2021
<乌鸦传媒>Scarring on an Otherwise Normal Heart: Reassuring Data Emerge Phenomenon tied to very low burden of major arrhythmic events Jul 14, 2021
<乌鸦传媒>Academic Cardiologists Singled Out for Gender Equality Problem Women still poorly represented, paid in procedural internal medicine specialties Jul 12, 2021
<乌鸦传媒>Skin Rash Should Be a Huge Red Flag for LVAD Recipients, Group Says New phenomenon suggests perils of not performing biopsy in time Jul 07, 2021
<乌鸦传媒>Regenerative Therapy Makes Headway in HF ... in the Right Patients Study of autologous skeletal cell-patch implantation in Japan Jul 02, 2021
<乌鸦传媒>First TTS Case After mRNA Shot; Fake Fellow Strikes Out; Disappearing Pacemaker Recent developments of interest in cardiovascular medicine Jun 29, 2021
<乌鸦传媒>First Close Look at Presumed Myocarditis Cases After COVID Vaccination Case reports suggest a favorable clinical course after hospitalization Jun 17, 2021
<乌鸦传媒>Best MIS-C Treatment? Murky Picture Emerges Large U.S. and international surveillance data series come to conflicting conclusions Jun 16, 2021
<乌鸦传媒>Early Vax Myocarditis Data; Novel RAAS Inhibitor; Star Athletes Collapse Mid-Game Recent developments of interest in cardiovascular medicine Jun 14, 2021
<乌鸦传媒>Op-Ed: Does Your Patient Really Have Diastolic Dysfunction? The Skeptical Cardiologist highlights the confusion in "diastology" Jun 05, 2021
<乌鸦传媒>Medtronic's LVAD Pulled From Market Due to Neurological, Mortality Risks Physicians must stop implanting the HeartWare system, says FDA Jun 03, 2021
<乌鸦传媒>Passing Early-Term Report Cards for New Mitral, Tricuspid Valve Interventions A glance at devices coming down the structural heart pipeline in the coming years May 24, 2021
<乌鸦传媒>Navitor Shuts Out Leaky TAVR, but Pacemaker Rates a Concern? 30-day data for a new version of the Portico valve May 20, 2021
<乌鸦传媒>Adverse Events Drop With Fuller Accounting of Evolut Low Risk Trial Yet worrying signals with TAVR remain May 19, 2021
<乌鸦传媒>Entresto Risky for Advanced Heart Failure? LIFE trial "not only disappointed but surprised" with its findings May 17, 2021
